An interventional study of Pulmonary rehabilitation program in Idiopathic Pulmonary Fibrosis and COPD, sponsored by Schön Klinik Berchtesgadener Land. Terminated at 1 site in Germany. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-13.
Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Health services research
Among 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany — 10 open to participants now, 17 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Germany.
Among the 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany, this one is the 67th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2019, is one of 7 with no phase, and was the 32nd registered.
576 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 123 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →10 of the 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United States, Argentina and 20 more countries
Avalyn Pharma Inc. · Sites in Germany, Australia, Canada and 4 more countries
Rein Therapeutics · Sites in Germany, United States, Australia and 4 more countries
AbbVie · Sites in Germany, United States, Australia and 14 more countries
Contineum Therapeutics · Sites in Germany, Argentina, Australia and 16 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 37 · Phase 3 17 · Phase 4 4
First in 2000; this study’s year is marked. 2 started in 2019.
This study's enrollment of 1 is below the median of 55 across 389 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 163 across the 68 interventional studies, 150 across the 8 observational. Of the 57 that completed or were terminated, 38 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 76 have an industry lead sponsor. The 10 most frequent:
Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Schön Klinik Berchtesgadener Land has 5 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Pulmonary Fibrosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07194382Avalyn Pharma Inc.AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | 2026-12 |
| NCT07036523Boehringer IngelheimA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | 2027-03-11 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT06968845Rein TherapeuticsA Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | 2027-09-30 |
Among the 76 studies in Idiopathic Pulmonary Fibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As the result of our last study "Long Term effects of an Inpatient Pulmonary Program in Patients with Pulmonary Fibrosis" already demonstrated the positive effects of a Pulmonary Rehabiliation on the mental status. In this current study the aim will be to analyse the personality type regarding anxiety and depression
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
\< 30% FVC comorbidities with a negativ influence on the prognosis neurological and orthopaedic deficits, which make the participation of the pulmonary rehabilitation impossible non-compliance no written of the patient
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Pulmonary rehabilitation program
Procedure: Pulmonary rehabilitation program
3 weeks, ...
Anxiety score
Hospital Anxiety and Depression scale
Time frame: 3 weeks
Anxiety score
Hospital Anxiety and Depression scale
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2019 to primary completion in Feb 2019, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →
Schön Klinik Berchtesgadener Land